5 Results for "

SHPT

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "SHPT" in MCE Product Catalog:

Cat. No.: HY-109106A
CAS No.: 2052969-18-1
Purity:  99.91%
Synonyms: SK-1403; AJT240; PLS240
Target:  

CaSR

Research Areas:  

Endocrinology

Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca 2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-109106
CAS No.: 1333218-50-0
Synonyms: SK-1403 free acid; AJT240 free acid; PLS240 free acid
Target:  

CaSR

Research Areas:  

Endocrinology

Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-109106B
CAS No.: 2649575-19-7
Purity:  ≥95.0%
Synonyms: (Rac)-SK-1403 free acid; (Rac)-AJT240 free acid; (Rac)-PLS240 free acid
Target:  

CaSR

Research Areas:  

Endocrinology

(Rac)-Upacicalcet is the racemate of Upacicalcet (HY-109106). Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-14863
CAS No.: 250384-82-8
Synonyms: CTA-018
Target:  

VD/VDR Cytochrome P450

Research Areas:  

Others Endocrinology

Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase. Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT) .
loading...
    loading...
Cat. No.: HY-109106AR
CAS No.: 2052969-18-1
Synonyms: SK-1403 (Standard); AJT240 (Standard); PLS240 (Standard)
Research Areas:  

Endocrinology

Upacicalcet sodium (Standard) is the analytical standard of Upacicalcet (sodium) (HY-109106A). This product is intended for research and analytical applications. Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic Kidney disease (CKd). Upacicalcet sodium is useful for studying SHPT .
loading...
    loading...